Intelligence for Nephrologists

Active Clinical Trials in
Nephrology in Brazil

Up-to-date overview of nephrology clinical trials recruiting patients in Brazil — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centres.

14
Active trials
73
Sites in Brazil
6
Indications covered
Carregando mapa…

14 studies found

Fase 3Nefropatia por IgA🇧🇷 6 sites in Brazil

A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301

Novartis Pharmaceuticals

📍 Belo Horizonte, Curitiba, Porto Alegre, São Paulo, Sao Jose Rio Preto👥 540 participants📅 Completion: 2032-10
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Glomeruloesclerose Focal e Segmentar (FSGS)🇧🇷 5 sites in Brazil

A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

Dimerix Bioscience Pty Ltd

📍 Botucatu, Recife, Rio de Janeiro, São Paulo👥 286 participants📅 Completion: 2029-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia por IgA🇧🇷 7 sites in Brazil

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression

Hoffmann-La Roche

📍 Belo Horizonte, Porto Alegre, Joinville, São Paulo, Rio de Janeiro👥 428 participants📅 Completion: 2026-08
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia por IgA🇧🇷 10 sites in Brazil

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Alexion Pharmaceuticals, Inc.

📍 Belo Horizonte, Botucatu, Curitiba, Fortaleza, Recife, Ribeirão Preto, São José do Rio Preto, São Paulo👥 510 participants📅 Completion: 2026-01
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Glomeruloesclerose Focal e Segmentar (FSGS)Doença de Lesões Mínimas🇧🇷 2 sites in Brazil

A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Sanofi

📍 São Paulo👥 84 participants📅 Completion: 2026-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Granulomatose Eosinofílica com PoliangiiteSíndrome Hipereosinofílica🇧🇷 1 site in Brazil

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

AstraZeneca

📍 São Paulo👥 14 participants📅 Completion: 2028-02
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Granulomatose com PoliangiitePoliangeíte Microscópica🇧🇷 4 sites in Brazil

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Novartis Pharmaceuticals

📍 Salvador, Barretos, São Paulo👥 126 participants📅 Completion: 2029-06
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia por IgA🇧🇷 7 sites in Brazil

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Biogen

📍 Belo Horizonte, Juiz de Fora, Caxias do Sul, Porto Alegre, São Paulo👥 454 participants📅 Completion: 2027-05
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Nefropatia Membranosa Primária🇧🇷 6 sites in Brazil

An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

Biogen

📍 Belo Horizonte, Porto Alegre, Ribeirão Preto, São José do Rio Preto, São Paulo👥 180 participants📅 Completion: 2028-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Nefropatia Membranosa Primária🇧🇷 6 sites in Brazil

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)

Climb Bio, Inc.

📍 Belo Horizonte, Minas Gerais, Pernambuco, Porto Alegre, São Paulo👥 45 participants📅 Completion: 2027-10
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Nefropatia Membranosa Primária🇧🇷 4 sites in Brazil

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants With PMN (Primary Membranous Nephropathy) Who Are at a High Risk for Disease Progression

Alexion Pharmaceuticals, Inc.

📍 Recife, Salvador, São Paulo👥 30 participants📅 Completion: 2027-02
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2Vasculite Associada a ANCA🇧🇷 7 sites in Brazil

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (I TRANSCEND)

Alexion Pharmaceuticals, Inc.

📍 Barretos, Belo Horizonte, Porto Alegre, Recife, São Paulo👥 75 participants📅 Completion: 2027-10
View details →Refer patient →ClinicalTrials.gov ↗
Fase 2, Fase 3Nefropatia Membranosa Primária🇧🇷 1 site in Brazil

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

Vertex Pharmaceuticals Incorporated

📍 São Paulo👥 176 participants📅 Completion: 2028-12
View details →Refer patient →ClinicalTrials.gov ↗
Fase 3Glomeruloesclerose Focal e Segmentar (FSGS)🇧🇷 7 sites in Brazil

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

Boehringer Ingelheim

📍 Campinas, Fortaleza, Porto Alegre, Recife, São Paulo👥 286 participants📅 Completion: 2029-11
View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Contact us →